Several studies in cohorts dominated by IDH-wildtype patients with GBM or comprising exclusively IDH-wildtype patients with GBM have shown that the survival of TMZ-treated patients with GBM can be divided into 3 or more groups on the basis of the extent of MGMT promoter methylation27–29. This evidence concerns the gene IDH2 and glioblastoma.